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OBJECTIVE: To obtain the confidence interval (CI) of
the results of a cost-effectiveness model for the treatment
of hypercholesterolemia.
BACKGROUND: Incremental CE ratios play an impor-
tant role in pharmacoeconomic analysis. However, CI es-
timates for the CE ratio are rare because the underlying
distribution is unknown in most cases. Rather than using
traditional one-way or multiway sensitivity analysis to
explore estimate variability, a nonparametric bootstrap
method is used to generate the CE ratio CI. This is more
robust because it does not make parametric assumptions.
METHODS: 1,000 bootstrap samples were drawn simul-
taneously with replacement from both an empirical distri-
bution and a Monte Carlo experiment. For patient risk
factors we used the complete subs ample of men aged 45-
64 fitting NCEP primary prevention guidelines in the Na-
tional Health and Nutrition Examination Survey III. For
model parameters (e.g., costs, discount rate) values were
randomly drawn from a specified multivariate distribu-
tion. With 1,000 repeated estimates, the 26th and 975th
ranked CE ratios were used to define the 95% confidence
interval. Programming was done in Visual Basic for Ap-
plications (VBA) language. The study perspective was
that of a third party payer. Efficacy and compliance data
were obtained from the WOSCOPS clinical trial. The in-
cremental 5-year cardiovascular health care costs were
derived from a health insurer database.
RESULTS: A 95% CI for the CE ratio resulting from the
nonparametric bootstrap method showed that primary
prevention of cardiovascular disease with pravastatin re-
mained cost-effective.
CONCLUSION: Confidence interval estimation for the
CE ratio is important and will allow individuals to iden-
tify if a new intervention is a good value for cost, while
capturing the inherent imprecision in the underlying CE
model parameter values.
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Abstracts
OBJECTIVE: The purpose of this study was to determine if
differences existed between pharmacological treatments of
peripheral arterial disease (and intermittent claudication)
(PADIIC) with respect to PADIIC-related costs and health
care outcomes in the Department of Defense (DOD) health
care system.
METHODS: A retrospective review of hospital and pre-
scription data was performed to explore the effects of an
exposure to at least 90 days of either aspirin, pentoxifyl-
line, or dypiridamole on various PAD-related outcomes.
The outcomes under study were the number of PAD-
related invasive procedures performed (INV), number of
PAD-related examination procedures performed (EXM),
number of PAD-related hospitalization days incurred
(HDAYS), and the cost of PAD-related procedures per-
formed (COST). The study period encompassed five
years. A covariate representing the pre-study period num-
ber of PAD-related hospitalizations was used to attempt
to control for severity of disease state. General linear
models (GLM) were used in the analyses.
RESULTS: A GLM showed a statistically significant dif-
ference among the treatment groups for a linear combina-
tion of INV, EXM, HDAYS, and COST when controlling
for past PAD-related hospitalizations (p < 0.02). A statis-
tically significant relationship was also found to exist be-
tween treatment groups and INV (p < 0.04). The pentox-
ifylline treatment group was shown to have a statistically
significant higher covariate-adjusted mean INV when
compared to the aspirin treatment group by a post-hoc T
test adjusted for alpha inflation (p = 0.04). Also, PAD-
related past hospitalizations showed a statistically signifi-
cant relationship with a EXM (p < 0.006).
CONCLUSION: The results appear to support the use of
aspirin in PAD as a preventative treatment.
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Smoking is a high-risk behavior that affects the health
and economic welfare of society. Thus, it is important to
quantify the economic burden smoking places on social
institutions in the United States.
OBJECTIVE: The purpose of this review paper is to ana-
lyze smoking cost studies and to provide estimates that
represent the economic costs of smoking from different
perspectives of society, and as a whole.
METHODS: Current Contents (1996-), Health Star
(1970-), and Medline (1966-) databases were searched
through the use of pertinent subject headings and key
words: tobacco use, smoking, cost, and economics. The
internet was utilized to identify potential sources of epi-
demiological and cost information on smoking. Recent
cost-of-illness studies using different methodologies: hu-
